83 related articles for article (PubMed ID: 3892088)
1. [Analogs of prostaglandin-related substances and inhibitors of their synthesis and metabolism. Clinical application: cardiovascular diseases].
Ogawa K; Ito T
Nihon Rinsho; 1985 Mar; 43(3):578-82. PubMed ID: 3892088
[No Abstract] [Full Text] [Related]
2. Selective thromboxane synthetase inhibitor and ischemic heart disease.
Ito T; Ogawa K; Watanabe J; Chen LS; Shikano M; Imaizumi M; Shibata T; Ito Y; Miyazaki Y; Satake T
Biomed Biochim Acta; 1984; 43(8-9):S125-32. PubMed ID: 6542777
[No Abstract] [Full Text] [Related]
3. Effects of selective thromboxane synthetase inhibitor OKY-046 on plasma prostaglandins in patients with coronary artery disease during exercise.
Shikano M; Ogawa K; Ito T; Chen LS; Ito Y; Imaizumi M; Uno T; Tsutsumi S; Satake T
Adv Prostaglandin Thromboxane Leukot Res; 1985; 13():375-7. PubMed ID: 3159226
[No Abstract] [Full Text] [Related]
4. [The efficacy of prostacyclin (PGI2) and/or OKY-046, a specific thromboxane synthetase inhibitor, in acute myocardial infarction--experimental study].
Moriuchi M
Kokyu To Junkan; 1984 Sep; 32(9):955-61. PubMed ID: 6393261
[No Abstract] [Full Text] [Related]
5. [Antithrombotic agents against platelet aggregation].
Tada M; Kuzuya T; Ohmori M
Nihon Rinsho; 1983 Dec; 41(12):2781-6. PubMed ID: 6687068
[No Abstract] [Full Text] [Related]
6. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
Aiken JW; Shebuski RJ; Miller OV; Gorman RR
J Pharmacol Exp Ther; 1981 Nov; 219(2):299-308. PubMed ID: 6270303
[No Abstract] [Full Text] [Related]
7. [Effect of the complex treatment of stable stenocardia on the status of the prostacyclin-thromboxane system].
Khimenko PL
Ter Arkh; 1986; 58(5):95-8. PubMed ID: 2874621
[TBL] [Abstract][Full Text] [Related]
8. Effects of dazoxiben on exercise performance in chronic stable angina.
Reuben SR; Kuan P; Cairns J; Gyde OH
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):83S-86S. PubMed ID: 6402000
[TBL] [Abstract][Full Text] [Related]
9. [Therapeutic prospects and prostaglandins in vascular pathology].
Courillon-Mallet A; Wautier JL
Arch Mal Coeur Vaiss; 1985 Dec; 78 Spec No():63-8. PubMed ID: 3938943
[TBL] [Abstract][Full Text] [Related]
10. Effects of dazoxiben on transcardiac thromboxane levels and haemodynamics in coronary heart disease.
Hutton I; Tweddel AC; Rankin AC; Walker ID; Davidson JF
Br J Clin Pharmacol; 1983; 15 Suppl 1(Suppl 1):79S-82S. PubMed ID: 6681709
[TBL] [Abstract][Full Text] [Related]
11. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
Varfolomeev SD; Lakin KM; Mevkh AT; Novikova NV; Rukazenkov IuZ
Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
[No Abstract] [Full Text] [Related]
12. Comparison of the thromboxane synthetase inhibitor dazoxiben and the prostacyclin mimetic iloprost in an animal model of acute ischaemia and reperfusion.
Thiemermann C; Schrör K
Biomed Biochim Acta; 1984; 43(8-9):S151-4. PubMed ID: 6083783
[TBL] [Abstract][Full Text] [Related]
13. [Analogs of prostaglandin-related substances and inhibitors of their formation and metabolism. Clinical application: respiratory diseases].
Hirose T
Nihon Rinsho; 1985 Mar; 43(3):587-91. PubMed ID: 3892090
[No Abstract] [Full Text] [Related]
14. [Biochemistry of coronary artery disease--prostaglandins].
Tada M; Kuzuya T; Ohmori M
Rinsho Byori; 1983 Aug; 31(8):854-9. PubMed ID: 6361336
[No Abstract] [Full Text] [Related]
15. Humoral heartache -- do platelets have a role?
Handin RI; Alexander RW
N Engl J Med; 1981 Apr; 304(17):1035-6. PubMed ID: 7010170
[No Abstract] [Full Text] [Related]
16. Effects of a selective inhibitor of thromboxane synthetase (OKY-1581) in humans.
Ito T; Ogawa K; Sakai K; Watanabe J; Satake T; Kayama N; Hiraku S; Naito J
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():245-51. PubMed ID: 6221531
[No Abstract] [Full Text] [Related]
17. [Clinical effects of urokinase and sodium ozagrel in patients with acute symptomatic lacunar infarction].
Sakamoto T; Harimoto K; Inoue S; Konishi A
No To Shinkei; 1996 Sep; 48(9):805-9. PubMed ID: 8888028
[TBL] [Abstract][Full Text] [Related]
18. Application of prostacyclin analogue and thromboxane synthetase inhibitor to chronic vascular rejection after kidney transplantation.
Teraoka S; Takahashi K; Toma H; Sanaka T; Yamaguchi Y; Tanabe K; Sato H; Kawaguchi H; Oba S; Nakajima I
Transplant Proc; 1987 Oct; 19(5):3664-8. PubMed ID: 3313883
[No Abstract] [Full Text] [Related]
19. Pharmacology of thromboxane synthetase inhibitors.
Aiken JW
Adv Prostaglandin Thromboxane Leukot Res; 1983; 11():253-8. PubMed ID: 6221532
[No Abstract] [Full Text] [Related]
20. [The effect of nitrates and miskleron on the prostacyclin-thromboxane ratio and on the functional activity of the thrombocytes in stenocardia patients].
Volkov VI; Ladnyĭ AI
Vrach Delo; 1989 Nov; (11):60-2. PubMed ID: 2514486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
